MediciNova asthma drug fails trial; shares crash

<p>(Reuters) – <span>Biopharmaceutical company</span> <span>MediciNova Inc</span> pronounced a initial <span>asthma drug</span> unsuccessful to accommodate a categorical idea of a second mid-stage trial, promulgation a shares down as most as 51 percent in extended trade.</p>
<p> <span>MediciNova</span>, that is contrast MN-221 as a diagnosis for strident asthma attacks not manageable to customary therapy, pronounced a drug showed no alleviation when compared with a <span>placebo</span>.</p>
<p> MN-221 looks to provide a condition by bypassing constricted airways to broach a drug directly into a lungs. It aims to urge FEV1 ratio when compared with a placebo.</p>
<p> FEV1 ratio measures volume of atmosphere exhaled in a initial second.</p>
<p> The trial, however, demonstrated a rebate in sanatorium admissions when <span&g...